DUBLIN, January 31, 2022–(BUSINESS WIRE)–The "Endometriosis – Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
The therapeutic market for endometriosis within the 7MM will grow from $1.061B in 2020 at a compound annual growth rate (CAGR) of 10.6% to $2.9B by 2030. In particular, the publisher expects the US market will contribute the most to the endometriosis market sales, accounting for roughly 68% of global sales in both 2020 ($730.65M) and 2030 ($577.1M).
The launch of GnRH antagonists relugolix and linzagolix across the 7MM will be the main drivers of growth during the forecast period. Other major drivers of growth include the launch of Quinagolide, the first endometriosis therapeutic that can treat pain without interfering with ovulation, and increased awareness of endometriosis, which leads to increased diagnosis rates.
The relugolix and linzagolix launch will provide the 5EU and Japanese markets with access to GnRH antagonists for the first time and should also bolster sales of AbbVie's GnRH antagonist Orilissa (elagolix), which is available in the US. Given the novelty of the endometriosis pipeline paired with the decrease in use of existing endometriosis-specific therapeutics, the publisher expects the GnRH antagonist class to account for the majority of global sales by 2030.
The consensus among interviewed physicians regarding the current treatment landscape of endometriosis is that there are several unmet needs that have persisted for decades, and that current marketed therapies are insufficient in treating pain without significant side effects. Key Opinion Leaders (KOLs) interviewed by the publisher highlighted the importance of decreasing diagnosis delays, which can be improved by better diagnostic procedures.
KOLs also discussed the need for a therapeutic that can treat endometriosis-associated pain while not affecting the patient's ability to conceive and treatments that can be used long-term.
The endometriosis market is currently highly genericized and contains many off-label medications, such as oral contraceptives and NSAIDs, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles compared with existing endometriosis marketed therapies.
The awareness surrounding endometriosis has improved over the past few years, but remains an area of concern, according to KOLs. Clinicians, physicians, and the general public all need to be more aware of the signs and symptoms of endometriosis in order to decrease diagnosis delays.
Women suffering from endometriosis wait an average of 7 years between symptom onset and diagnosis, during which time the disease can progress significantly, potentially affecting fertility. This diagnosis delay can be improved not only with increased awareness of endometriosis, but also better diagnostic techniques, such as biomarkers. Endometriosis can only be officially diagnosed via laparoscopy, which is an invasive and costly surgical procedure.
Orilissa was the first novel therapy launched in the endometriosis market in over 10 years when it was marketed in 2018. Thus, there is a need for novel therapies in this space, which should be met by the promising pipeline.
Key Questions Answered
Treatment for endometriosis should improve over the forecast period, but unmet needs remain.
Which unmet needs are the most pressing in the 7MM?
Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
Novel GnRH antagonists are being developed, with GnRH antagonists reaching the 5EU and Japan for the first time during the forecast period.
What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
What do KOLs say about their clinical and commercial positioning?
An increasing number of companies are investing in women's health and endometriosis with some entering into large-scale collaborations, such as Evotec and Bayer, in an effort to produce more endometriosis therapies.
Which have been historically the companies leading the way?
What new companies are emerging in the space?
Key Topics Covered:
1 Endometriosis: Executive Summary
1.1 The Endometriosis Market Will Exhibit Considerable Growth Between 2020 and 2030
1.2 Current Therapies Leave Significant Unmet Needs in the Endometriosis Market
1.3 There Is a High Unmet Need for Earlier Endometriosis Diagnosis
1.4 Pipeline Therapies Present Promise in Closing Treatment Gaps
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Prevalent Cases of Endometriosis
4.4.4 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy Confirmation Status
4.4.5 Diagnosed Prevalent Cases of Endometriosis by ASRM Stage
4.4.6 Diagnosed Prevalent Cases of Endometriosis by Phenotype
4.4.7 Germany and the UK
4.4.8 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy
4.4.9 Diagnosed Prevalent Cases of Endometriosis with Comorbidities
4.5 Epidemiological Forecast for Endometriosis (2020-2030)
4.5.1 Diagnosed Prevalent Cases of Endometriosis
4.5.2 Age-Specific Diagnosed Prevalent Cases of Endometriosis
4.5.3 Diagnosed Prevalent Cases of Endometriosis by Laparoscopy
4.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage
4.5.5 Diagnosed Prevalent Cases of Endometriosis by Phenotype
4.5.6 Diagnosed Prevalent Cases of Endometriosis Undergoing Laparoscopy
4.5.7 Diagnosed Prevalent Cases of Endometriosis with Comorbidities
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Key Opinion Leader Insights on Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.2 Noninvasive Diagnostics
7.3 Disease Awareness and Education of Medical Professionals
7.4 More Effective Drugs with Long-Term Safety and Tolerability
7.5 Non-Hormonal Therapies
7.6 Better Understanding of the Disease Etiology and Pathophysiology
8 R&D Strategies
8.1.1 Reformulations and Label Expansion
8.1.2 The Race for the Development of GnRH Antagonists
8.1.3 Development of Novel Non-Hormonal Therapies
8.2 Clinical Trial Design
8.2.1 Pain Scales
8.2.2 Quality of Life Assessment as an Efficacy Tool
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Competitive Assessment
11 Current and Future Players
11.1.6 Additional Companies
11.2 Deal-Making Trends
12 Market Outlook
For more information about this report visit https://www.researchandmarkets.com/r/h0vayg
View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005660/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Yahoo Finance's Anjalee Khemlani gives an update on FDA authorization for COVID-19 vaccines from Moderna and Novavax.
(Bloomberg) — New studies are emerging that suggest the latest version of the highly-infectious omicron variant is transmitting even faster than the original, and mild cases of the first may not offer much protection against future infections. Most Read from BloombergTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsCovid-Infected HIV Patient Developed Mutations, Study ShowsAn Army of Faceless Suits Is Taking Over the $4 Trillion Hedge Fund WorldNasdaq 100 Notches B
Is Pfizer stock a buy or a sell after the company backed out of a deal with Ionis Pharma? Is PFE stock a buy now?
Shares of Provention Bio (NASDAQ: PRVB) were skyrocketing 30.8% higher as of 3:41 p.m. ET on Monday. The big jump continued the momentum that began on Friday after the drugmaker announced that it intends to refile for approval of teplizumab for delaying type 1 diabetes. As a result, Provention plans to resubmit its Biologic License Application (BLA) for the experimental therapy within the next couple of months.
Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by as much as 18% in pre-market action Monday morning. The gains came in response to a positive top-line readout from a phase 3 clinical trial for resmetirom, its experimental fatty liver disease drug candidate. Madrigal said that the drug was safe and well-tolerated at both the 80 mg and 100 mg dose levels assessed in the trial.
Healthcare, one of the largest and most complex sectors, is composed of a broad range of companies that sell medical products and services. The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers. The healthcare sector has caught investors’ attention since some of these companies have received regulatory approval for drugs to treat COVID-19 and begun distributing vaccines.
Dr. Howard Forman, Yale professor and 'Health & Veritas' podcast co-host, joins Yahoo Finance Live to discuss the COVID-19 'stealth' variant, vaccination in the U.S., the rise in coronavirus cases among athletes ahead of the Olympics in China, and the outlook for the pandemic.
Investors might have forgotten what the color green looks like after all the non-stop selling in the stock market lately. Healthcare technology stocks have gone through a particularly rough stretch, with some popular names down more than 50% from their highs. The strong fundamentals and growth opportunities ahead make these three stocks potential winners over the long term even if they look like losers today.
Dr. Manish Garg, an emergency medicine physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance Live to discuss COVID-19 cases, flu and booster shots, and vaccines for children under age 4.
The Omicron variant of COVID-19 continues to sweep across the U.S., and although new cases have peaked in some areas, in other areas they're continuing to climb. Experts say three things are clear about Omicron at this point: It's highly contagious, it seems to cause less severe illness than previous variants, and it's still very important to protect yourself against it. Even though Omicron may lead to serious illness in a smaller percentage of people, it's causing so many new cases that health
Both the mother and baby are doing well, the United Airlines said on Monday
The BA.2 subvariant of the Omicron coronavirus variant, which has quickly taken over in Denmark, is more transmissible than the more common BA.1 and more able to infect vaccinated people, a Danish study has found. The study, which analysed coronavirus infections in more than 8,500 Danish households between December and January, found that people infected with the BA.2 subvariant were roughly 33% more likely to infect others, compared to those infected with BA.1. Worldwide, the "original" BA.1 subvariant accounts for more than 98% of Omicron cases, but its close cousin BA.2 has quickly become the dominant strain in Denmark, dethroning BA.1 in the second week of January.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2.
The new company's approach, which is expected to enter an early-stage clinical trial this year, could both activate and suppress the immune system's response to solid tumors.
Founded in 2011, the Conshohocken company has grown to about 50 employees and is led by the husband-and-wife team.
‘Lewis’ star tested positive days after sharing a photo in T-shirt reading: ‘No vaccine needed. I have an immune system’
Brooks Free Library's Confidential Corner isn't a big set of shelves, but the books there could become hugely important to someone who needs help.
A man died and a woman was taken to the hospital after a hit-and-run crash in a parking lot, Houston police say.
Democrats in Florida’s state senate said, “Aiight, Imma head out,” on Thursday rather than listen to the state’s surgeon general, Dr. Joseph Ladapo, avoid giving direct answers about his beliefs on Covid-19 vaccines.
Here's how many Owen County residents have received the COVID-19 vaccine as of Jan. 24, according to data.